Scarica l'app Stockscreener
156.00
2.17%
3.315
Dopo l'orario di chiusura:
156.01
0.005
+0.00%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie
Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $185.00 - MarketBeat
Ligand Pharmaceuticals shares rise 3.65% intraday after pricing $400 million convertible senior notes offering. - AInvest
Ligand's $400M Convertible Notes Offering: A Strategic Move for M&A-Driven Growth and Shareholder Value - AInvest
Ligand Prices $400 Million Convertible Senior Notes Offering - MarketScreener
Ligand Pharmaceuticals Prices Offering Of $400 Mln Of Senior Notes - Nasdaq
Ligand Pharmaceuticals Experiences Strong Q2 Earnings with Robust Revenue Growth, Successful Mergers and Investments, and Raised Financial Guidance. - AInvest
Analysts Bullish on Insmed and Ligand Pharma: Strong Buy Ratings and High Price Targets - AInvest
Ligand Pharmaceuticals Secures $400M in Convertible Debt Offering - AInvest
Ligand Pharmaceuticals' Convertible Notes Offering: A Strategic Move for Capital Optimization and Growth - AInvest
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering | LGND Stock News - GuruFocus
Ligand Pharmaceuticals prices $400 million convertible notes offering By Investing.com - Investing.com Canada
Ligand's Convertible Notes Offering: Balancing Dilution Risks and Strategic Flexibility in Biopharma Financing - AInvest
Ligand Pharmaceuticals Prices $400 Million Convertible Senior Notes Due 2030 - Quiver Quantitative
Ligand Secures $400M Convertible Note Deal: Key Terms Reveal 0.75% Rate and $15M Share Buyback - Stock Titan
Ligand prices $400 million convertible senior notes offering - MarketScreener
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering - GlobeNewswire Inc.
Ligand Pharmaceuticals Inc. Reports Strong Q2 Earnings - TipRanks
LGND: Getting In Tune with MedTech - Zacks Small Cap Research
Ligand Pharma Proposes Private Offering Of $400 Mln Of Sr. Notes - Nasdaq
Ligand Pharmaceuticals shares fall 4.06% premarket after announcing a $400 million convertible senior notes offering. - AInvest
Ligand Announces $400M Convertible Senior Notes Offering Due 2030. - AInvest
Ligand Pharmaceuticals plans $400 million convertible notes offering By Investing.com - Investing.com Canada
Ligand Pharmaceuticals to Offer $400mln Convertible Senior Notes Due 2030. - AInvest
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 - Stock Titan
Ligand's Q2 2025: Unraveling Contradictions in Pelthos Launch, Deal Strategies, and Market Dynamics - AInvest
Will Ligand Pharmaceuticals Incorporated Recover After Recent DeclineStable Entry High Return Opportunities in Focus - beatles.ru
A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $157 to $185 - 富途牛牛
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2025 Earnings Call Transcript - Insider Monkey
Ligand: RBC Raises PT to $185, Maintains Outperform Rating - AInvest
Ligand Pharma stock price target raised to $185 from $155 at RBC Capital - Investing.com Canada
Ligand Pharmaceuticals Among 3 Stocks Possibly Trading Below Intrinsic Value Estimates - Yahoo Finance
Ligand Pharmaceuticals Q2 2025 Earnings Call Highlights: Robust Royalty Growth and Strategic Partnerships - AInvest
Ligand Pharmaceuticals Raises FY25 EPS and Revenue Outlook, Boosts EPS View to $6.70-$7.00 and Revenue View to $200M-$225M. - AInvest
Ligand Pharmaceuticals Reports Q2 EPS and Revenue Above Consensus, Raises 2025 Guidance - AInvest
Ligand Pharmaceuticals Inc (LGND) Q2 2025 Earnings Call Highlights: Robust Royalty Growth and ... By GuruFocus - Investing.com Canada
Ligand Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Ligand Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Ligand Pharmaceuticals Raises 2025 Revenue Guidance to $225M Amid Royalty Portfolio Momentum - AInvest
Transcript : Ligand Pharmaceuticals Incorporated, Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Pelthos Therapeutics shares rise 2.00% after-hours following Ligand Pharmaceuticals' Q2 revenue increase of 15%. - AInvest
Ligand Pharma stock price target raised to $167 by Oppenheimer on strong royalty growth - Investing.com Canada
Earnings call transcript: Ligand Pharmaceuticals Q2 2025 beats forecasts, stock rises - Investing.com Canada
Ligand Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ligand: Q2 Earnings Snapshot - San Francisco Chronicle
Ligand Q2 2025 presentation: 57% royalty growth drives raised guidance By Investing.com - Investing.com Canada
Ligand Pharmaceuticals Q2 2025 Earnings: Revenue Surpasses Estimates at $47.6M, EPS Falls Short at $0.24 - GuruFocus
Ligand Pharmaceuticals Reports 57% Increase in Royalty Revenue and Raises 2025 Financial Guidance - Quiver Quantitative
Ligand Pharmaceuticals Q2 revenue up 15%, raises 2025 guidance - MarketScreener
Ligand Q2 revenue up 57% YoY, FY23 guidance raised to $200-$225 mln. - AInvest
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance - GlobeNewswire
Ligand Pharmaceuticals Reports Q2 2025 Financial Results - TradingView
Press Release: Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance - 富途牛牛
Investors in Ligand Pharmaceuticals (NASDAQ:LGND) Have Seen Notable Returns of 36% Over the Past Year - 富途牛牛
Ligand Pharmaceuticals stock hits 52-week high at 143.31 USD By Investing.com - Investing.com Nigeria
Ligand Pharmaceuticals stock hits 52-week high at 143.31 USD - Investing.com India
Ligand LGND 2025Q2 Earnings Preview Upside Ahead on Robust Revenue Growth - AInvest
Ligand Pharmaceuticals Incorporated Sees Relief Buying After Extended DropReal Trader Watchlist of Hot Stocks Released - metal.it
Price Channel Expanding on Ligand Pharmaceuticals Incorporated’s ChartReal Time Trade Opportunity Alerts Monitor Market Surges - metal.it
What is the risk reward ratio of investing in Ligand Pharmaceuticals Incorporated stockHigh-yield investments - Jammu Links News
How does Ligand Pharmaceuticals Incorporated compare to its industry peersDiscover undervalued opportunities early - Jammu Links News
Why is Ligand Pharmaceuticals Incorporated stock attracting strong analyst attentionAchieve rapid financial growth with smart picks - Jammu Links News
What makes Ligand Pharmaceuticals Incorporated stock price move sharplyFastest return on investment - Jammu Links News
Is Ligand Pharmaceuticals Incorporated a good long term investmentCapitalize on momentum-driven opportunities - Jammu Links News
Ligand Pharmaceuticals to meet with Oppenheimer on July 28-29 - AInvest
Ligand Pharmaceuticals Incorporated to Host Earnings Call - ACCESS Newswire
Orchestra BioMed secures $70 million from Ligand and Medtronic By Investing.com - Investing.com South Africa
Orchestra BioMed secures $70 million from Ligand and Medtronic - Investing.com
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed - GlobeNewswire
$70M Strategic Investment Powers Orchestra BioMed's Revolutionary Leadless Pacemaker Technology - Stock Titan
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):